Nintedanib Reveals Remarkable Efficacy in Alleviating Progressive Pulmonary Fibrosis Symptoms
In the groundbreaking INBUILD trial, researchers discovered that nintedanib can significantly improve the lives of patients suffering from progressive pulmonary fibrosis (PPF). Nintedanib holds promise not only in reducing the progression of dyspnea, fatigue, and cough but also in mitigating the overall impact of ILD over 52 weeks in patients grappling with PPF.
The trial results were published in the journal European Respiratory Journal.
Pulmonary fibrosis, a condition characterized by scarring of the lungs, often leads to symptoms such as dyspnea (shortness of breath) and cough, profoundly impacting patients' daily lives. Hence, researchers conducted a trial, that focused on the effects of nintedanib on PPF symptoms using the Living with Pulmonary Fibrosis (L-PF) questionnaire to assess changes in patients' conditions.
The trial included 663 patients with fibrosing interstitial lung disease (ILD), excluding idiopathic pulmonary fibrosis, but with more than 10% lung involvement on high-resolution computed tomography (HRCT) scans and evidence of ILD progression within the past 24 months. Patients were randomly assigned to receive either nintedanib or a placebo, with researchers analyzing L-PF questionnaire scores from baseline to week 52 using mixed models for repeated measures.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.